Using Clostridium Butyricum Miyairisan to treat symptoms of Parkinson's Disease
Official title: The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease
Run by Kaohsiung Medical University Chung-Ho Memorial Hospital · NCT06548256 · Data updated 2026-11-12
This study is testing if a treatment called Clostridium Butyricum Miyairisan can help improve both movement and daily life for people with Parkinson's disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 90 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung City) |
| Status | Recruiting |
| Started | October 31, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 12, 2024 |
| Trial ID | NCT06548256 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 20 years old who have been diagnosed with Parkinson's disease.
✕Probably not a fit
Patients with Parkinson's disease dementia or lactose intolerance may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of Clostridium Butyricum Miyairi in alleviating both motor and non-motor symptoms in patients with Parkinson's disease. It is an open-label, single-center, non-randomized trial where participants will receive the treatment and undergo assessments to measure outcomes. The study aims to gather data on how this intervention impacts the quality of life for those affected by Parkinson's disease.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the management of symptoms in Parkinson's disease patients.
How similar studies have gone: While this approach is relatively novel, similar studies exploring gut microbiota and neurological conditions have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female over 20 years old, diagnosed with Parkinson's disease. Exclusion Criteria: * People with Parkinson's disease Dementia, or Lactose Intolerance
Where it's running
-
Kaohsiung Medical Univeristy Hospital
Kaohsiung City, Taiwan Recruiting
Study contacts
- Study coordinator: Yang-Pei Chang, M.D.; MSc.
- Email: cyp905@gmail.com
- Phone: 886-7-2911101
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.